Celltrion is expanding its global prescription reach by presenting the clinical results of its autoimmune disease treatment, 'Remsima SC,' at an international conference. The company aims to continuously secure clinical evidence to promote its prescriptions in the global market.
From June 25, Celltrion is presenting clinical data on Remsima SC (ingredient name: infliximab) at the 'Asian Conference on Inflammatory Bowel Disease (AOCC) and the International Conference of the Korean Society of Gastroenterology (IMKASID)' held in Seoul.
The study being presented involves the results of a Phase 3 clinical trial conducted on 60 patients with Crohn's disease in Japan. Patients who achieved remission with the intravenous (IV) formulation were switched to the subcutaneous (SC) formulation, and their effectiveness and safety were monitored over 44 weeks.
According to the results, clinical remission and endoscopic remission were maintained stably after the switch to the SC formulation. No new safety concerns were identified.
This data was previously presented at the American Gastroenterological Association's Digestive Disease Week (DDW). Its reintroduction at this conference is seen as an effort to increase awareness among healthcare professionals.
During the conference, Celltrion, along with its subsidiary Celltrion Pharmaceutical, will operate a separate booth and share strategies based on actual prescription data. On June 26, a session featuring international healthcare professionals will discuss their prescription experiences.
On the same day, a luncheon symposium will feature Professor Silvio Danese from San Raffaele University in Italy and Professor Hong Seong-no from Samsung Medical Center, who will present on real-world prescribing experiences with the infliximab SC formulation and the role of therapeutic drug monitoring (TDM).
According to IQVIA, a pharmaceutical market research firm, Celltrion's Remsima product line for autoimmune diseases recorded a combined market share of 70% in Europe as of the fourth quarter of last year. This figure reaffirms its dominant leadership in the infliximab market.
Notably, the performance in the five major European countries (EU5) is remarkable, with shares of 83% in the UK, 82% in France, and 80% in Italy, demonstrating a strong competitive advantage.
The growth of Remsima SC, which emphasizes convenience, is also steep. In Germany, it surpassed 50% market share, while in France, it reached 36%, expanding its territory. In some countries like Greece and Luxembourg, its market share is nearing 100%, effectively monopolizing the market.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.